Blinatumomab overcomes poor prognostic impact of measurable residual disease in pediatric high-risk first relapse B-cell precursor acute lymphoblastic leukemia.
Franco LocatelliCornelia EckertOndrej HrusakBarbara BuldiniMary SartorGerhard ZugmaierYi ZengDeepali PilankarJoan MorrisArend von StackelbergPublished in: Pediatric blood & cancer (2022)
Blinatumomab was more efficacious than HC3 regardless of MRD status before treatment. These data support the role of blinatumomab in inducing deep MRD remission, negating the poor prognostic value of MRD.